martes, 12 de mayo de 2020

BioEdge: How can we speed up vaccine trials?

BioEdge: How can we speed up vaccine trials?

Bioedge

How can we speed up vaccine trials?
    
Thirty-five members of the US Congress have written to health authorities in the Trump Administration asking them to authorise accelerated trials to find a vaccine for the coronavirus. “Every week of delay in the deployment of a vaccine to the seven billion humans on Earth will cost thousands of lives,” they declare.
The route to a quick-fix vaccine passes through “challenge trials” – deliberately infecting human volunteers with the virus to see whether or not a vaccine works. A safe vaccine can take a decade to develop – the fastest have taken four years. But the devastation wreaked by the coronavirus has convinced a number of doctors, scientists and ethicists that it is worth taking the risk. 
Challenge trials are not new. They have been used in the past to test medications – but for diseases which are well known, like influenza or cholera. A few hundred young and healthy volunteer participants would be given a placebo or the trial vaccine.
In a traditional clinical trial the participants would go about their daily lives until some of them were infected. In a challenge trial the volunteers, who are first given either the potential vaccine or a placebo, are deliberately infected. Researchers would be able to tell quickly whether the vaccine was safe and effective.
This approach could cut months, even years, off the time needed to make it available and for people to resume normal social life.
There are numerous problems with challenge trials. For one, it is risky. People in their 20s – from whom the participants would probably be drawn --- seldom become very sick with Covid-19. But there have been some deaths. Participants would have to appreciate the risks. 
But as the American politicians write, “Our situation in this pandemic is analogous to war, in which there is a long tradition of volunteers risking their health and lives on dangerous missions for which they understand the risks and are willing to do so in order to help save the lives of others.”
The idea has sparked a heated debate amongst scientists and bioethicists. Arthur Caplan, a bioethicist at New York University, and Stanley Plotkin, a renowned vaccinologist who helped invent the rubella vaccine, endorsed the idea in an article in the journal Vaccine. (In this interview in Vice, Caplan makes a forceful, non-technical argument for challenge trials.) Plotkin claimed in an article in Science that a well-designed challenge trial could yield clear proof within two or three months. 
A website set up to recruit volunteers for challenge trials, 1 Day Sooner, says that more than 9,000 people have signed up from 52 countries . 
However, the US Food and Drug Administration is more cautious. “The FDA is exploring all possible options to most efficiently advance the development of safe and effective vaccines that will prevent COVID-19,” agency spokesman Michael Felberbaum told The Hill. “Human challenge studies used to develop a COVID-19 vaccine may present ethical and feasibility issues that can be avoided with the use of animal models.”
Myron Levine, an expert in challenge trials at Maryland School of Medicine, believes that conventional methods will yield results very quickly because of the level of infection in some locations. He is sceptical about challenge trials. “I cannot imagine that it would be ethical and would really speed up what we have to do,” he told Science.
Ethics, science, manufacturing, distribution: it’s important for researchers to cover all the bases, lest they end up with a catastrophe like thalidomide. Or like the situation which Will Smith’s character has to deal with in the zombie thriller I Am Legend. Watch Emma Thompson explain how her cancer cure works in this brilliant interview. And then it didn’t.
Michael Cook is editor of BioEdge
Bioedge

Like rivets popping on a sinking ship, the stresses of the pandemic are revealing the weakness in our societies. Suddenly we realise how much we depend on humble workers who provide essential services, how much we depend on supply chains, how vulnerable the elderly are, and so on.

One statistic that caught my eye was the number of over-65s in care per thousand of population. This came up as part of Donald Trump's boast that the per capita death rate in the United States is far lower than the highest nation, which was Belgium. There's a reason for that -- Belgium is counting many deaths in nursing homes as deaths from coronavirus, even if the people had not been tested.

But a chart in the BBC story showed that Belgium also has the the third highest proportion of people in nursing homes in Europe, 71 per thousand. Even higher were the Netherlands (75) and Luxembourg (82). Is it a coincidence that these three countries have also legalised euthanasia? What does that figure say about their social structure? After the pandemic has passed, I hope someone follows this up.      
NEWS THIS WEEK
by Michael Cook | May 03, 2020
It’s going to be ethically controversial
 
 
by Michael Cook | May 03, 2020
Parliament has not decoupled ‘mother’ from gender
 
 
by Michael Cook | May 03, 2020
Ioannides attacked over sceptical views on lockdowns
 
 
by Michael Cook | May 03, 2020
Is is a ‘moral imperative’?
 
 
by Michael Cook | May 03, 2020
New film about cryogenically frozen Iranian writer
 
 
by Michael Cook | May 03, 2020
Opening up cosmetic surgery clinics      
Bioedge

BioEdge
Level 1, 488 Botany Road, Alexandria NSW 2015 Australia
Phone: +61 2 8005 8605
Mobile: 0422-691-615

No hay comentarios: